期刊文献+

17β-雌二醇逆转乳腺癌耐药蛋白介导的多药耐药机制 被引量:2

THE STUDY OF THE MECHANISM OF 17β-ESTRADIOL ON REVERSAL OF THE BREAST CANCER RESISTANT PROTEIN-MEDIATED MULTIDRUG RESISTANCE
下载PDF
导出
摘要 目的探讨17β-雌二醇逆转乳腺癌耐药蛋白(BCRP)介导的非典型多药耐药的机制。方法分别通过药物诱导和转基因的方法建立由BCRP和巨细胞病毒(CMV)启动子启动表达BCRP的两种耐药细胞系MCF-7/MX20和MCF-7/BCRP,将耐药细胞培养在含有17β-雌二醇的培养基中,通过细胞毒性实验,外排实验以及定量PCR观察对不同耐药细胞系的逆转作用。结果培养基中加入17β-雌二醇48h后,MCF-7/BCRP细胞中的米托蒽醌的强度明显低于MCF-7/MX20,MCF-7/BCRP细胞中BCRP mRNA的含量明显高于MCF-7/MX20。17β-雌二醇可以抑制细胞中BCRP的表达和功能,但是不能抑制MCF-7/BCRP细胞中BCRP的表达和功能。结论17β-雌二醇不是作为BCRP的底物而抑制BCRP功能的,而可能是通过调控BCRP基因的启动子发挥作用。 Objective To explore the mechanism of the reversal of breast cancer resistant protein-mediated multidrug resistance by 17β-estradiol. Methods Two BCRP expressing cell lines of MCF-7/MX20 and MCF-7/BCRP were established in which breast canrcer resistant protein(BCRP) was promoted by BCRP promoter and cytomegalovirus(CMV) promoter respectively, These drug resistant cell lines were cultured in medium containing 17β-estradiol. Fourty-eight hours later, cytotoxicity assay, mitoxantrone efFlux assays, quantitative BT-PCR were performed to observe the reversal function of BCRP by 17β-estradiol on MCF- 7/MX20 and MCF-7/BCRP respectively. Results After being treated with 17β-estradiol,the intensity of mitoxantrone in MCF-7/ BCRP was weaker than that in MCF-7/MX20 and the BCRP mRNA level in MCF-7/BCRP was high than that in MCF-7/MX20.The results of these experiments revealed that 17β-estradiol could reverse the BCRP mediated multidrug resistance(MDR) in MCF-7/ MX20 cells but not in MCF-7/BCRP ones. Conclusion 17β-estradiol may reverse the phenotype of BCRP through regulation of the promoter of BCRP gene but not acted as the substrate of BCRP.
出处 《解剖学报》 CAS CSCD 北大核心 2007年第1期43-46,共4页 Acta Anatomica Sinica
基金 国家自然科学基金资助项目(30300124) 高等学校博士学科点专项基金资助项目(20020422042)
关键词 雌激素 乳腺癌耐药蛋白 基因调控 启动子 耐药逆转 Estrogen Breast cancer resistant protein Gene regulation Promoter Reversal of drug resistance
  • 相关文献

参考文献14

  • 1Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-depending transporters[J]. Nat Rev Cancer, 2002,2 ( 1 ) : 48- 58.
  • 2李文通,周庚寅,宋现让,迟伟玲,任瑞美,王兴武.MCF-7/BCRP细胞系的建立及其生物学特征[J].山东大学学报(医学版),2005,43(6):469-472. 被引量:3
  • 3Robey RW, Honjo Y, van de Laar A, et 81. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2) [ J]. Biochim Biophys Acta, 2001, 1512(2) : 171-182.
  • 4Faneyte IF, Kristel PM, Maliepaard M, et al. Expression of the breast cancer resistance protein in breast cancer[J]. Clin Cancer Res, 2002, 8(4) : 1068-1074.
  • 5Burger H, Foekens JA, Look MP, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrugproteins 1 and 2, and multidrug resistance gene 1in breast cancer: correlation with chemotherapeutic response[J]. ClinCancer Res, 2003, 9(2): 827-836.
  • 6Rocchi E, Khodjakov A, Volk EL, et al. rrne product of the ABC halftransporter gene ABCG2(BCRP/MXR/ABCP) is expressed in the plasma membrane[J]. Biochem Biophys Res Commun, 2000, 271(1) :42-46.
  • 7Kage K, Tsukahara S, Sugiyama T, et al. Dominant-negative inhibition of breast cancer resistance protein as drug efllux pump through the inhibition of S-S dependent homodimerization [ J]. Int J Cancer, 2002, 97(5) :626-630.
  • 8Ejendal KF, Hrycyna CA. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2[J]. Curr Protein Pept Sci, 2002, 3 (5) : 503-511.
  • 9de Bruin M, Miyake K, Litman T, et al. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR[J]. Cancer Lett, 1999, 146(2):117-126.
  • 10Rabindran SK, Ross DD, Doyle LA, et al. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance proteln[J]. Cancer Res, 2000, 60(1):47-50.

二级参考文献8

  • 1Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells[J]. Proc Natl Acad Sci USA, 1998, 95(26):15 665~15 670.
  • 2Robert W Robey, Yasumasa Honjo, Anne van de Laar,et al. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2) [J].Biochem et Biophys Acta, 2001, 1512: 171~182.
  • 3Ross DD, Yang W, Abruzzo LV, et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines [J]. J Natl Cancer Inst, 1999, 91: 429~433.
  • 4Xu J, Liu Y, Yang Y, et al. Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2 [J]. J Biol Chem, 2004, 279:19 781~19 789.
  • 5Sridhar K Rabindran, Douglas D Ross, L Austin Doyle,et al. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein1 [J]. Cancer Res, 2000, 60: 47~50.
  • 6Allen JD, van Loevezijn A, Lakhai JM, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C [J]. Mol Cancer Ther, 2002, 1: 417~425.
  • 7Abbott BL, Colapietro AM, Barnes Y, et al. Low levels of ABCG2 expression in adult AML blast samples [J].Blood, 2002, 100:4 594~4 601.
  • 8Kowalski P, Stein U, Scheffer GL, et al. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2 [J]. Cancer Gene Ther, 2002, 9:579~586.

共引文献2

同被引文献37

  • 1曾爱华,何蕴韶,韩非.BCRP基因在乳腺癌组织中的表达及意义[J].山东医药,2005,45(1):14-16. 被引量:13
  • 2DOYLE LA, YANG W, ABRUZZO LV, et al. A multidrug resistance transporter from human MCF-7 breaat cancer cells [J]. Proc Natl Sci USA, 1998, 95(26): 15665-15670.
  • 3XU J, PENG H, CHEN Q, et al. Oligomerization domain of the muhidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity [J]. Cancer Res, 2007, 67 (9) : 4373-4381.
  • 4LIU Y, YANG Y, QI J, et al. Effect of cysteine mutagenesis on the function and disulfide bond formation of human ABCG2[J]. J Pharmacol Exp Ther, 2008, 326(1): 33-40.
  • 5AHMED F, ARSENI N, GLIMM H, et al. Constitutive expression of the ATP-binding cassette transporter ABCG2 enhances the growth potential of early human hematopoietic progenitors[J]. Stem Cells, 2008, 26(3): 810-818.
  • 6IFERGAN I, JANSEN G, ASSARAF YG. Cytoplasmic confinement of breast cancer resistance protein (BCRP/ABCG2) as a novel mechanism of adaptation to short-term folate deprivation [J]. Mol Pharmacol, 2005, 67 (4) : 1349-1359.
  • 7IFERGAN I, SHAFRAN A, JANSEN G, et ol. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression[J]. J Biol Chem, 2004, 279(24): 25527-25534.
  • 8KPdSHNAMURTHY P, ROSS DD, NAKANISHI T, et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme [J]. J Biol Chem, 2004, 279 (23) : 24218-24225.
  • 9KRISHNAMURTHY P, SCHUETZ JD. The ABC transporter Abcg2/Bcrp: role in hypoxia mediated survival [J]. Biometals, 2005, 18(4): 349-358.
  • 10VANDER BORGHT S, van PELT J, van MALENSTEIN H, et al.Up-regulation of breast cancer resistance protein expression in hepatoblastoma following chemotherapy: A study in patients and in vitro[J]. Hepatol Res, 2008, 38(11): 1112-1121.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部